We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: phase 3 trial
MedXY News
EnglishTag

phase 3 trial

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial Review
Clinical UpdatesanbenitamabHB1801

Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial Review

By MedXY|Sep 6, 2026

This review synthesizes evidence from a phase 3 trial demonstrating improved pathological complete response rates with neoadjuvant anbenitamab and HB1801 in ERBB2-positive breast cancer, highlighting efficacy, safety, and clinical implicati

Veligrotug Delivers Rapid, Durable Benefit in Active Thyroid Eye Disease in the Phase 3 THRIVE Trial
Diabetes & EndocrinologyIGF-1R
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
phase 3 trial

Veligrotug Delivers Rapid, Durable Benefit in Active Thyroid Eye Disease in the Phase 3 THRIVE Trial

By MedXY|Jun 6, 2026

In phase 3 testing, veligrotug produced rapid and clinically meaningful reductions in proptosis, diplopia, and disease activity in active thyroid eye disease, with durable benefit through 52 weeks and a favorable short-term safety profile.

Intraperitoneal and Intravenous Paclitaxel Plus S-1 Improves Survival in Gastric Cancer With Peritoneal Metastasis: Phase 3 Trial
GastroenterologyGastric Cancerintraperitoneal chemotherapy

Intraperitoneal and Intravenous Paclitaxel Plus S-1 Improves Survival in Gastric Cancer With Peritoneal Metastasis: Phase 3 Trial

By MedXY|May 25, 2026

A phase 3 trial found that adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improved survival in gastric cancer with peritoneal metastasis without increasing severe toxicity.

Rationale and Design of CARDIO-TTRansform: A Phase 3 Trial of Eplontersen for Transthyretin Amyloid Cardiomyopathy
CardiologyCARDIO-TTRansformcardiovascular outcomes

Rationale and Design of CARDIO-TTRansform: A Phase 3 Trial of Eplontersen for Transthyretin Amyloid Cardiomyopathy

By MedXY|May 10, 2026

CARDIO-TTRansform is a global Phase 3 trial evaluating eplontersen’s efficacy and safety in reducing cardiovascular events in transthyretin amyloid cardiomyopathy patients receiving standard care, including TTR stabilizers. With 1,432

EuTCV Vi‑CRM197 (Single‑ and Multidose) Is Non‑Inferior to Typbar TCV in Infants and Well Tolerated Across Age Groups in Kenya and Senegal
Infectious Diseasesimmunogenicityphase 3 trial

EuTCV Vi‑CRM197 (Single‑ and Multidose) Is Non‑Inferior to Typbar TCV in Infants and Well Tolerated Across Age Groups in Kenya and Senegal

By MedXY|Nov 30, 2025

A multicentre phase 3 trial shows single‑ and multidose EuTCV (Vi‑CRM197) are immunologically non‑inferior to Typbar TCV in infants 9–12 months, with comparable safety and reactogenicity across ages — supporting WHO prequalification.

Advancing First-Line Treatment in Metastatic NSCLC: The Promise of Retifanlimab Combined with Chemotherapy
Oncologychemotherapyimmunotherapy

Advancing First-Line Treatment in Metastatic NSCLC: The Promise of Retifanlimab Combined with Chemotherapy

By MedXY|Oct 18, 2025

This article reviews the phase 3 POD1UM-304 trial demonstrating that adding retifanlimab to platinum-based chemotherapy improves overall survival in first-line metastatic NSCLC, highlighting its potential as a new standard of care.

Optimizing Treatment in Frail Elderly with Newly Diagnosed Multiple Myeloma: Insights from the IFM2017-03 Trial on Dexamethasone-Sparing Daratumumab and Lenalidomide Regimen
Hematology-OncologydaratumumabDexamethasone

Optimizing Treatment in Frail Elderly with Newly Diagnosed Multiple Myeloma: Insights from the IFM2017-03 Trial on Dexamethasone-Sparing Daratumumab and Lenalidomide Regimen

By MedXY|Oct 15, 2025

The IFM2017-03 phase 3 trial demonstrates that a dexamethasone-sparing regimen combining daratumumab with lenalidomide markedly improves progression-free survival in frail elderly multiple myeloma patients, without increasing serious advers

Efficacy and Safety of Ecnoglutide, a cAMP-Biased GLP-1 Receptor Agonist, in Weight Management for Overweight and Obese Adults: Insights from a Phase 3 Multicentre Randomised Trial
Diabetes & EndocrinologyEcnoglutideGLP-1 receptor agonist

Efficacy and Safety of Ecnoglutide, a cAMP-Biased GLP-1 Receptor Agonist, in Weight Management for Overweight and Obese Adults: Insights from a Phase 3 Multicentre Randomised Trial

By MedXY|Oct 5, 2025

This review synthesizes evidence from a multicentre, phase 3 trial on ecnoglutide, demonstrating significant and sustained weight loss in overweight/obese adults without diabetes, with a favorable safety profile, supporting its clinical use

Comparative Efficacy of Induction-Concurrent Versus Concurrent-Adjuvant Chemoradiotherapy in High-Risk N2-N3 Nasopharyngeal Carcinoma: Insights from a Phase 3 Randomized Trial
Oncologyadjuvant chemotherapychemoradiotherapy

Comparative Efficacy of Induction-Concurrent Versus Concurrent-Adjuvant Chemoradiotherapy in High-Risk N2-N3 Nasopharyngeal Carcinoma: Insights from a Phase 3 Randomized Trial

By MedXY|Oct 4, 2025

A phase 3 trial showed no significant difference in 3-year progression-free survival between induction-concurrent and concurrent-adjuvant chemoradiotherapy in treating high-risk N2-N3 nasopharyngeal carcinoma, with both regimens exhibiting

Selumetinib for Adults with NF1-Associated Inoperable Plexiform Neurofibromas: Results from the KOMET Phase 3 Trial
Clinical Updatesneurofibromatosis type 1phase 3 trial

Selumetinib for Adults with NF1-Associated Inoperable Plexiform Neurofibromas: Results from the KOMET Phase 3 Trial

By MedXY|Oct 1, 2025

The KOMET phase 3 trial shows selumetinib offers significant tumor response in adults with NF1 and inoperable plexiform neurofibromas, with a manageable safety profile.

Mitapivat Offers New Hope for Adults with Non-Transfusion-Dependent α- and β-Thalassaemia: Results from the Phase 3 ENERGIZE Trial
Clinical Updatesmitapivatphase 3 trial

Mitapivat Offers New Hope for Adults with Non-Transfusion-Dependent α- and β-Thalassaemia: Results from the Phase 3 ENERGIZE Trial

By MedXY|Oct 1, 2025

Mitapivat significantly improves haemoglobin levels in adults with non-transfusion-dependent α- or β-thalassaemia, offering a promising oral therapeutic option with manageable safety profile.

Inebilizumab for Generalized Myasthenia Gravis: Results from a Phase 3 Randomized Trial
Clinical Updatesinebilizumabmonoclonal antibody

Inebilizumab for Generalized Myasthenia Gravis: Results from a Phase 3 Randomized Trial

By MedXY|Sep 30, 2025

A phase 3 trial shows inebilizumab, a CD19+ B-cell depleting antibody, improves function and reduces disease severity in generalized myasthenia gravis without increasing serious adverse events.

Tarlatamab versus Chemotherapy in Relapsed Small-Cell Lung Cancer: Results from the Phase 3 DeLLphi-304 Trial
Clinical Updatesimmunotherapyphase 3 trial

Tarlatamab versus Chemotherapy in Relapsed Small-Cell Lung Cancer: Results from the Phase 3 DeLLphi-304 Trial

By MedXY|Sep 30, 2025

Tarlatamab significantly improves overall survival and reduces severe adverse events compared to chemotherapy in patients with small-cell lung cancer progressing after platinum-based therapy.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities